Abstract Details

Title The pharmacokinetics of SAGE-217 in Phase 1 SAD and MAD studies

Topic Movement Disorders

Presentation(s) P3 - (-)

Poster/Presentation
Number 008

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Ethan Hoffman PRESENTER	No disclosure on file
	No disclosure on file
Shane Raines	Shane Raines has received personal compensation for serving as an employee of 2b Analytics, LLC.
George Nomikos	No disclosure on file
Helen Colquhoun	Helen Colquhoun has received personal compensation for serving as an employee of Sage Therapeutics. Helen Colquhoun has stock in Sage Therapeutics. Helen Colquhoun has received intellectual property interests from a discovery or technology relating to health care.
Stephen Kanes	No disclosure on file

��ɫ����